Sugi Predict

Sugi Predict / Compounds / SCHEMBL1305286

SCHEMBL1305286

SCHEMBL1305286

O=[P](c1ccc(F)cc1)c1ccc(F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 1/20 0.39
▸ CES1 P23141 1/20 0.39
▸ CA1 P00915 4/20 0.38
▸ CA2 P00918 4/20 0.38
▸ CA7 P43166 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ ACHE P22303 1/20 0.38
▸ IDO1 P14902 1/20 0.33
▸ BCL2L1 Q07817 1/20 0.33
▸ BAD Q92934 1/20 0.33
▸ ORAI1 Q96D31 1/20 0.33
▸ ORAI2 Q96SN7 1/20 0.33
▸ ORAI3 Q9BRQ5 1/20 0.33
▸ TRPV6 Q9H1D0 1/20 0.33
▸ LOXL2 Q9Y4K0 1/20 0.33
▸ MGLL Q99685 1/20 0.33
▸ KCNN4 O15554 1/20 0.32
▸ PTPN1 P18031 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ MMP1 P03956 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2153492 0.89 NFE2L2 (0.41) CES2CES1BCL2L1BADKCNN4
SCHEMBL28518753 0.87 ACHE (0.62) ACHEALDH1A1
SCHEMBL28370567 0.83 NFE2L2 (0.55) CA1CA2CA7CA9ACHE
SCHEMBL28363230 0.73 FFAR4 (0.42) ACHEALDH1A1
SCHEMBL196718 0.73 CYP3A4 (0.44) CES2CES1CA1CA2CA7
Bromide SCHEMBL28417395 0.71 CYP3A4 (0.42) CES2CES1CA1CA2CA7
SCHEMBL5713320 0.71 CYP3A4 (0.42) CES2CES1CA1CA2CA7
SCHEMBL7933208 0.71 CA1 (0.40) CES2CES1CA1CA2CA7
SCHEMBL13499 0.71 — —
SCHEMBL7526444 0.69 CES2 (0.46) CES2CES1CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118908996-A A composition containing C (sp2) P bond or C (sp)3) Process for preparing organic phosphine compound of-P bond 烟台大学 2024-11-08 — — CN claimed
CN-114031639-B Preparation method of biphospide with P-O-C-P structure 烟台大学 2024-07-12 — — CN claimed
CN-113583042-B Preparation method of phosphoryl fluoride compound 烟台大学 2023-08-29 — — CN claimed
CN-113583042-A Preparation method of phosphoryl fluoride compound 烟台大学 2021-11-02 — — CN claimed
CN-107312035-B The synthetic method of triaryl phosphine 南京理工大学 2019-05-07 — — CN claimed
EP-2046491-B1 SULFONATED POLYARYLENE COMPOUNDS, MEMBRANE MATERIAL MADE THEREFROM, METHOD FOR THE PRODUCTION THEREOF, AND USE LEIBNIZ INST POLYMERFORSCHUNG (DE) 2010-05-12 — — EP claimed
US-5756848-A Process for preparing secondary arylphosphine oxides HOECHST AKTIENGESELLSCHAFT 1998-05-26 — — US claimed
CN-119613454-A Preparation method of difluoromethyl-containing compound 昆明理工大学 2025-03-14 — — CN disclosed
CN-119431439-A Method for preparing 2-formylaryl (phosphinic) phosphine/phosphoramide compound 岳阳凯茂化工材料有限公司 2025-02-14 — — CN disclosed
CN-116041392-B Compound containing phosphate group, preparation method and application thereof 中国科学院长春应用化学研究所 2024-11-12 — — CN disclosed
CN-118908996-A A composition containing C (sp2) P bond or C (sp)3) Process for preparing organic phosphine compound of-P bond 烟台大学 2024-11-08 — — CN disclosed
CN-115403623-B Method for preparing 2-pyrrolyl substituted phosphine oxide compound 湖南理工学院 2024-10-29 — — CN disclosed
CN-114031639-B Preparation method of biphospide with P-O-C-P structure 烟台大学 2024-07-12 — — CN disclosed
US-7678942-B2 Process for preparation of diphosphine compounds and intermediates for the process TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-16 — — US disclosed
EP-1452537-B1 PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS TAKEDA PHARMACEUTICAL (JP) 2009-08-05 — — EP disclosed
US-20070161805-A1 Phosphine-borane complex enantiomorph compounds produced in solvents and in the presence of nickel catalysts; useful for asymmetric synthesis of compounds useful as drug for prophylaxis or treatment of increased urinary frequency or urinary incontinence, Alzheimer's disease SPERA PHARMA, INC. (JP) 2007-07-12 — — US disclosed
US-7208633-B2 Process for preparation of diphosphine compounds and intermediates for the process TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-04-24 — — US disclosed
US-20050027124-A1 Process for preparation of diphosphine compounds and intermediates for the process SPERA PHARMA, INC. (JP) 2005-02-03 — — US disclosed
EP-1452537-A1 PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS Takeda Chemical Industries, Ltd. (JP) 2004-09-01 — — EP disclosed
US-5756848-A Process for preparing secondary arylphosphine oxides HOECHST AKTIENGESELLSCHAFT 1998-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161805-A1 Phosphine-borane complex enantiomorph compounds produced in solvents and in the presence of nickel catalysts; useful for asymmetric synthesis of compounds useful as drug for prophylaxis or treatment of increased urinary frequency or urinary incontinence, Alzheimer's disease BACE1, H1-10, PRMT1 CES2 1349/4885CES1 2337/4885CA1 109/4885
US-20050027124-A1 Process for preparation of diphosphine compounds and intermediates for the process H1-10, ITPA, RER1 CES2 4480/4885CES1 4790/4885CA1 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.